{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:49Z","timestamp":1793643169401,"version":"4.5.1"},"reference-count":162,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32GM082773-13"],"award-info":[{"award-number":["5T32GM082773-13"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1053\/j.gastro.2021.04.063","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T11:20:32Z","timestamp":1619781632000},"page":"47-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":261,"title":["Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User\u2019s Guide for Adult and Pediatric Gastroenterologists"],"prefix":"10.1053","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-1485","authenticated-orcid":false,"given":"Manasi","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.04.063_bib1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn's disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib4","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and future burden of inflammatory bowel diseases based on modeling of population-based data","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn's & Colitis Foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ibd\/izaa082","article-title":"High disease burden drives indirect costs in employed inflammatory bowel disease patients: the WORK-IBD study","volume":"27","author":"van Gennep","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib9","doi-asserted-by":"crossref","unstructured":"Brochard C, Rabilloud ML, Hamonic S, et\u00a0al. Natural history of perianal Crohn's disease: long-term follow-up of a population-based cohort [published online ahead of print December 24, 2020]. Clin Gastroenterol Hepatol https:\/\/doi.org\/10.1016\/j.cgh.2020.12.024.","DOI":"10.1016\/j.cgh.2020.12.024"},{"key":"10.1053\/j.gastro.2021.04.063_bib10","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1097\/MIB.0000000000000846","article-title":"Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong","volume":"22","author":"Ng","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib11","doi-asserted-by":"crossref","unstructured":"Agrawal M, Bento-Miranda M, Walsh S, et\u00a0al. Prevalence and progression of incidental terminal ileitis on non-diagnostic colonoscopy: a systematic review and meta-analysis [published online ahead of print February 14, 2021]. J Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab030.","DOI":"10.1093\/ecco-jcc\/jjab030"},{"key":"10.1053\/j.gastro.2021.04.063_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ecco-jcc\/jjx066","article-title":"Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort","volume":"11","author":"Burisch","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","article-title":"Treat to target: a proposed new paradigm for the management of Crohn's disease","volume":"13","author":"Bouguen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/ibd\/izy374","article-title":"A\u00a010-year follow-up study of the natural history of perianal crohn's disease in a danish population-based inception cohort","volume":"25","author":"Zhao","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib18","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/ibd\/izz334","article-title":"Continued statural growth in older adolescents and young adults with Crohn's disease and ulcerative colitis beyond the time of expected growth plate closure","volume":"26","author":"Gupta","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib19","doi-asserted-by":"crossref","first-page":"S-469","DOI":"10.1016\/S0016-5085(20)31854-0","article-title":"SA1895 Validation of the L\u00e9mman index in Crohn's disease","volume":"158","author":"Pariente","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"A\u00a0prospective multicentre study of 121 cases. The Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn's disease digestive damage score, the L\u00e9mann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn's Disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/apt.15885","article-title":"Quality improvement project identifies factors associated with delay in IBD diagnosis","volume":"52","author":"Walker","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/ecco-jcc\/jjz065","article-title":"Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn's disease","volume":"13","author":"Schoepfer","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib26","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1007\/s10620-016-4189-z","article-title":"Diagnostic delay is associated with a greater risk of early surgery in a French cohort of Crohn's disease patients","volume":"61","author":"Nahon","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2021.04.063_bib27","doi-asserted-by":"crossref","unstructured":"Blackwell J, Saxena S, Jayasooriya N, et\u00a0al. Prevalence and duration of gastrointestinal symptoms before diagnosis of Inflammatory Bowel Disease and predictors of timely specialist review: a population-based study [published online ahead of print July 15, 2020]. J Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa146.","DOI":"10.1093\/ecco-jcc\/jjaa146"},{"issue":"9","key":"10.1053\/j.gastro.2021.04.063_bib28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/ibd\/izz265","article-title":"Cost burden of crohn's disease and ulcerative colitis in the 10-year period before diagnosis\u2013A Danish register-based study from 2003-2015","volume":"26","author":"Vadstrup","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0016-5085(93)90883-E","article-title":"Growth failure in children with inflammatory bowel disease: a prospective study","volume":"105","author":"Motil","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/gut.34.7.939","article-title":"Growth and clinical course of children with Crohn's disease","volume":"34","author":"Griffiths","year":"1993","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/2050640620947579","article-title":"Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease","volume":"8","author":"Rodr\u00edguez-Lago","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2021.04.063_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ecco-jcc\/jjv067","article-title":"Development of Red Flags Index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative","volume":"9","author":"Danese","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A\u00a0meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib36","doi-asserted-by":"crossref","unstructured":"Fiorino G, Bonovas S, Gilardi D, et\u00a0al. Validation of the Red Flags Index for early diagnosis of Crohn's disease: a prospective observational IG-IBD study among general practitioners [published online ahead of print September 28, 2020]. J Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa111.","DOI":"10.1093\/ecco-jcc\/jjaa111"},{"key":"10.1053\/j.gastro.2021.04.063_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"Supple 3","key":"10.1053\/j.gastro.2021.04.063_bib39","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2018","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib41","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn's disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3748\/wjg.v16.i2.232","article-title":"Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario","volume":"16","author":"Roth","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib45","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/ibd.20897","article-title":"Risk factors and characteristics of extent progression in ulcerative colitis","volume":"15","author":"Etchevers","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib46","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izz259","article-title":"Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies","volume":"26","author":"Ouahed","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/j.gastro.2021.04.063_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.meg.0000108337.41221.08","article-title":"Crohn's disease in the over-60 age group: a population based study","volume":"16","author":"Heresbach","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib48","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","article-title":"Systematic Review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease","volume":"10","author":"Ananthakrishnan","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib49","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib50","doi-asserted-by":"crossref","unstructured":"Faye AS, Wen T, Soroush A, et\u00a0al. Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD [published online ahead of print January 1, 2020]. Dig Dis Sci https:\/\/doi.org\/10.1007\/s10620-020-06746-w.","DOI":"10.1007\/s10620-020-06746-w"},{"key":"10.1053\/j.gastro.2021.04.063_bib51","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/MCG.0000000000001204","article-title":"Race\/ethnicity-specific disparities in in-hospital mortality and hospital charges among inflammatory bowel disease-related hospitalizations in the United States","volume":"54","author":"Galoosian","year":"2020","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/apt.15107","article-title":"Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors","volume":"49","author":"Agrawal","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/ajg.2011.85","article-title":"Differences in inflammatory bowel disease phenotype between South Asians and Northern Europeans living in North West London, UK","volume":"106","author":"Walker","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjz139","article-title":"Viewpoint: inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations","volume":"14","author":"Agrawal","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib55","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2021.04.063_bib56","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/ibd\/izy004","article-title":"Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies","volume":"24","author":"Severs","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib57","doi-asserted-by":"crossref","first-page":"e1418","DOI":"10.1542\/peds.2007-0905","article-title":"Gender differences in presentation and course of disease in pediatric patients with Crohn disease","volume":"120","author":"Gupta","year":"2007","journal-title":"Pediatrics"},{"key":"10.1053\/j.gastro.2021.04.063_bib58","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/ibd.21617","article-title":"Sex differences in statural growth impairment in Crohn's disease: role of IGF-1","volume":"17","author":"Gupta","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib59","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib60","author":"Sandborn"},{"key":"10.1053\/j.gastro.2021.04.063_bib61","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjw116","article-title":"Predicting outcomes to optimize disease management in inflammatory bowel diseases","volume":"10","author":"Torres","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib62","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cgh.2020.04.060","article-title":"Factors associated with development of perianal fistulas in pediatric patients with Crohn's disease","volume":"19","author":"Singer","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib63","doi-asserted-by":"crossref","first-page":"S659","DOI":"10.1016\/S0016-5085(19)38553-1","article-title":"Su1916\u2013Absence of perianal symptoms does not mean no perianal fistula in Crohn\u2019s disease: base on MRI examination","volume":"156","author":"Zhi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib64","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12876-018-0928-2","article-title":"Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study","volume":"19","author":"Qiu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib66","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib67","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/gutjnl-2018-318074","article-title":"Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis","volume":"68","author":"Limketkai","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib68","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.cgh.2019.03.040","article-title":"Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark","volume":"17","author":"Burisch","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib69","doi-asserted-by":"crossref","unstructured":"Attauabi M, Zhao M, Bendtsen F, et\u00a0al. Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases [published online ahead of print July 6, 2020]. Inflamm Bowel Dis https:\/\/doi.org\/10.1093\/ibd\/izaa167.","DOI":"10.1093\/ibd\/izaa167"},{"key":"10.1053\/j.gastro.2021.04.063_bib70","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2021.04.063_bib71","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/MIB.0b013e318281f506","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease","volume":"19","author":"Gathungu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib72","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2008.12.046","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease","volume":"136","author":"Han","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib73","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":"Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib74","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/archdischild-2018-316584","article-title":"Calprotectin instability may lead to undertreatment in children with IBD","volume":"105","author":"Haisma","year":"2020","journal-title":"Arch Dis Child"},{"key":"10.1053\/j.gastro.2021.04.063_bib75","first-page":"26","article-title":"The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis","volume":"9","author":"Lasson","year":"2014","journal-title":"J\u00a0Crohns"},{"key":"10.1053\/j.gastro.2021.04.063_bib76","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2019.05.055","article-title":"Preanalytical heterogeneity in fecal calprotectin measurement needs to be considered for tight control","volume":"18","author":"Pansart","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib78","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.cgh.2019.02.017","article-title":"Association between level of fecal calprotectin and progression of Crohn's disease","volume":"17","author":"Kennedy","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib79","doi-asserted-by":"crossref","unstructured":"Plevris N, Fulforth J, Lyons M, et\u00a0al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn's disease [published online ahead of print August 13, 2020]. Clin Gastroenterol Hepatol https:\/\/doi.org\/10.1016\/j.cgh.2020.08.022.","DOI":"10.1016\/j.cgh.2020.08.022"},{"key":"10.1053\/j.gastro.2021.04.063_bib80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.04.063_bib81","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","article-title":"A\u00a0frameshift mutation in NOD2 associated with susceptibility to Crohn's disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.04.063_bib82","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2021.04.063_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib84","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2021.04.063_bib85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A\u00a0validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables","volume":"43","author":"Siegel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib86","doi-asserted-by":"crossref","first-page":"S-729","DOI":"10.1016\/S0016-5085(20)32502-6","article-title":"The prevalence of incidental terminal ileitis in persons undergoing non-diagnostic colonoscopy: a meta-analysis","volume":"158","author":"Agrawal","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib87","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib88","series-title":"RENFLEXIS\u00ae (infliximab-abda) [package insert]","year":"2020"},{"key":"10.1053\/j.gastro.2021.04.063_bib89","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.cgh.2019.08.012","article-title":"Stopping mesalamine therapy in patients with Crohn's disease starting biologic therapy does not increase risk of adverse outcomes","volume":"18","author":"Ungaro","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib90","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjaa050","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","volume":"14","author":"Targownik","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib91","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.063_bib92","doi-asserted-by":"crossref","first-page":"S-53","DOI":"10.1016\/S0016-5085(20)30816-7","article-title":"279. Combination therapy does not improve clinical and endoscopic remission rates with vedolizumab or ustekinumab in Crohn's disease and ulcerative colitis","volume":"158","author":"Hu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib93","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","article-title":"Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy","volume":"14","author":"Pan\u00e9s","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOG.0000000000000361","article-title":"Surgical rates in the era of biological therapy: up, down or unchanged?","volume":"33","author":"Olivera","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib95","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial","volume":"2","author":"Ponsioen","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial","volume":"5","author":"Stevens","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib97","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/gutjnl-2018-317539","article-title":"Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial","volume":"68","author":"de Groof","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2007.03431.x","article-title":"Meta-analysis: enteral nutrition in active Crohn's disease in children","volume":"26","author":"Dziechciarz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib99","first-page":"8","article-title":"Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children","volume":"31","author":"Heuschkel","year":"2000","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.04.063_bib100","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/apt.12770","article-title":"Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome","volume":"39","author":"Frivolt","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.063_bib101","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.gastro.2019.04.021","article-title":"Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial","volume":"157","author":"Levine","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib102","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3748\/wjg.v19.i43.7652","article-title":"Use of exclusive enteral nutrition in adults with Crohn's disease: a review","volume":"19 43","author":"Wall","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib104","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cgh.2019.11.054","article-title":"Diet in treatment of inflammatory bowel diseases","volume":"19","author":"Sasson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.063_bib106","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.063_bib107","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib108","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib109","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib111","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib112","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib113","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib114","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib115","first-page":"75","article-title":"Vedolizumab-induced de novo extraintestinal manifestations","volume":"16","author":"Diaz","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib116","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib117","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohn's disease","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib118","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cgh.2020.04.078","article-title":"Development and validation of a clinical decision support tool that incorporates pharmacokinetic data to predict endoscopic healing in patients treated with infliximab","volume":"19","author":"Vande Casteele","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib119","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib120","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib121","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib122","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3508","article-title":"NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity","volume":"48","author":"Moriyama","year":"2016","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2021.04.063_bib123","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41436-019-0448-7","article-title":"Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry","volume":"21","author":"Schaeffeler","year":"2019","journal-title":"Genet Med"},{"key":"10.1053\/j.gastro.2021.04.063_bib124","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3093","article-title":"HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants","volume":"46","author":"Heap","year":"2014","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2021.04.063_bib125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1\u221705 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib126","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2020.03.073","article-title":"Extended analysis identifies drug-specific association of 2 distinct HLA class II haplotypes for development of immunogenicity to adalimumab and infliximab","volume":"159","author":"Powell Doherty","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib127","first-page":"21","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2021.04.063_bib128","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib129","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","article-title":"Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins","volume":"158","author":"D'Haens","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib131","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.cgh.2019.10.042","article-title":"Response assessed by ultrasonography as target of biological treatment for Crohn\u2019s disease","volume":"18","author":"Zorzi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib132","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/gutjnl-2019-319451","article-title":"Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study","volume":"69","author":"Maaser","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.063_bib133","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2016.10.040","article-title":"Use of intestinal ultrasound to monitor Crohn's disease activity","volume":"15","author":"Kucharzik","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib134","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2013.10.055","article-title":"Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease","volume":"146","author":"Ordas","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib135","first-page":"716","article-title":"Accuracy of diffusion-weighted magnetic resonance colonography in assessing mucosal healing and the treatment response in patients with ulcerative colitis","volume":"11","author":"Laurent","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib136","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cgh.2014.03.035","article-title":"Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib137","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib138","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/ecco-jcc\/jjaa092","article-title":"Therapeutic drug monitoring of anti-tumour necrosis factor agents in inflammatory bowel diseases: the jury is still out","volume":"14","author":"Agrawal","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib139","first-page":"1079","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study","volume":"12","author":"Guidi","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib140","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib142","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib143","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","article-title":"Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease","volume":"18","author":"Dreesen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib144","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.cgh.2018.04.007","article-title":"Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home","volume":"16","author":"Regueiro","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib145","doi-asserted-by":"crossref","first-page":"S-413","DOI":"10.1016\/S0016-5085(20)31723-6","article-title":"Sa1761. An interdisciplinary care program for recently diagnosed inflammatory bowel disease patients is associated with increased clinical remission rates and lower steroid use","volume":"158","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.063_bib146","first-page":"186","article-title":"Transforming access to specialist care for inflammatory bowel disease: the PACE Telemedicine Program","volume":"2","author":"Habashi","year":"2019","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib147","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial","volume":"390","author":"de Jong","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.063_bib148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MPG.0b013e31825959b8","article-title":"Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations","volume":"55","author":"Rufo","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.04.063_bib149","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ibd.20266","article-title":"Receipt of preventive health services by IBD patients is significantly lower than by primary care patients","volume":"14","author":"Selby","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MPG.0000000000000730","article-title":"Survey of immunization practices in patients with inflammatory bowel disease among pediatric gastroenterologists","volume":"61","author":"Lester","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.04.063_bib152","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11938-019-00231-8","article-title":"Diet as adjunctive treatment for inflammatory bowel disease: review and update of the latest literature","volume":"17","author":"Damas","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.063_bib153","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib154","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ibd.22850","article-title":"An integrated model of care for inflammatory bowel disease sufferers in Australia: development and the effects of its implementation","volume":"18","author":"Mikocka-Walus","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib155","doi-asserted-by":"crossref","unstructured":"Sehgal P, Ungaro RC, Foltz C, et\u00a0al. High levels of psychological resilience associated with less disease activity, better quality of life, and fewer surgeries in inflammatory bowel disease [published online ahead of print July 22, 2020]. Inflamm Bowel Dis https:\/\/doi.org\/10.1093\/ibd\/izaa196.","DOI":"10.1093\/ibd\/izaa196"},{"key":"10.1053\/j.gastro.2021.04.063_bib156","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ecco-jcc\/jju007","article-title":"Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases","volume":"9","author":"Langhorst","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.063_bib157","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/MIB.0000000000000773","article-title":"Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy: the COMPLIANT Study","volume":"22","author":"Nguyen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib158","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/MIB.0000000000001194","article-title":"Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn's disease and ulcerative colitis","volume":"23","author":"Tiao","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MPG.0000000000002207","article-title":"Inflammatory bowel diseases and school absenteeism","volume":"68","author":"Eloi","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.04.063_bib160","first-page":"1092","article-title":"Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs","volume":"23","author":"Manceur","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1053\/j.gastro.2021.04.063_bib161","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MIB.0000000000001048","article-title":"Communication between physicians and patients with ulcerative colitis: reflections and insights from a qualitative study of in-office patient-physician visits","volume":"23","author":"Rubin","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.063_bib162","first-page":"Cd001431","article-title":"Decision aids for people facing health treatment or screening decisions","author":"Stacey","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2021.04.063_bib163","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.063_bib164","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support\u00a0monitoring of vedolizumab trough concentrations\u00a0in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521007344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521007344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:49:47Z","timestamp":1762163387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521007344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0016508521007344"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.04.063","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User\u2019s Guide for Adult and Pediatric Gastroenterologists","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.04.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}